NCT00659503View on ClinicalTrials.gov

Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)

PHASE3CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

April 30, 2005

Study Completion Date

November 30, 2005

Conditions
Rhinitis, Allergic, SeasonalHay Fever
Interventions
DRUG

Ciclesonide

200µg Ciclesonide versus Placebo

DRUG

Placebo

placebo

Trial Locations (1)

K7L2V7

Altana/Nycomed, Kingston

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT00659503 - Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407) | Biotech Hunter | Biotech Hunter